Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Countries citing papers authored by Gavin Giovannoni
Since
Specialization
Citations
This map shows the geographic impact of Gavin Giovannoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Giovannoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Giovannoni more than expected).
Fields of papers citing papers by Gavin Giovannoni
This network shows the impact of papers produced by Gavin Giovannoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Giovannoni. The network helps show where Gavin Giovannoni may publish in the future.
Co-authorship network of co-authors of Gavin Giovannoni
This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Giovannoni.
A scholar is included among the top collaborators of Gavin Giovannoni based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Gavin Giovannoni. Gavin Giovannoni is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Middleton, Rod, Jeff Rodgers, Gavin Giovannoni, et al.. (2017). A Comparison of participant supplied EDSS scores and clinically submitted data via the UK MS Register. Cronfa (Swansea University).15 indexed citations
7.
Álvarez-González, César, Joela Mathews, Sharmilee Gnanapavan, et al.. (2017). Treating multiple sclerosis with generic cladribine. Queen Mary Research Online (Queen Mary University of London).1 indexed citations
8.
Meier, Ute‐Christiane, Tove Christensen, Daniel R. Altmann, et al.. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. UCL Discovery (University College London).1 indexed citations
9.
Lynham, Steven, et al.. (2016). A comprehensive characterisation of the salivary proteome of patients with Parkinson's disease. UCL Discovery (University College London).1 indexed citations
10.
Lu, Ching‐Hua, Corrie Macdonald‐Wallis, Elizabeth Gray, et al.. (2015). Neurofilament light chain. Neurology. 84(22). 2247–2257.390 indexed citations breakdown →
Lidster, Katie, Samuel J. Jackson, Peter Coffey, et al.. (2011). Neuroprotection in a novel optic neuritis model. UCL Discovery (University College London).1 indexed citations
13.
Vermersch, Patrick, Giacomo P. Comi, Gavin Giovannoni, et al.. (2011). Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study. UCL Discovery (University College London).1 indexed citations
14.
Pryce, Gareth, Sandra Amor, Wouter H. Gerritsen, et al.. (2011). Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. UCL Discovery (University College London).1 indexed citations
Rieckmann, Peter, G. Comi, Sandra Cook, et al.. (2009). Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. UCL Discovery (University College London).9 indexed citations
17.
Farrell, Rachel & Gavin Giovannoni. (2007). Development and validation of luciferase reporter gene assay to measure anti-interferon beta neutralizing antibodies. UCL Discovery (University College London).1 indexed citations
18.
Martino, Davide, Giovanni Defazio, Russell C. Dale, et al.. (2006). Soluble adhesion molecules in Gilles de la Tourette's syndrome (vol 234, pg 79, 2005). UCL Discovery (University College London).2 indexed citations
19.
Edwards, Mark J., Davide Martino, Maria Bozi, et al.. (2004). Anti-basal ganglia antibodies in patients with atypical dystonia and tics - A prospective study. UCL Discovery (University College London).1 indexed citations
20.
Dale, Russell C., et al.. (2002). Re-emergence of encephalitis lethargica-like syndrome: Evidence of CNS autoimmunity. UCL Discovery (University College London).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.